Abstract: The invention concerns a device for the capillary transport of a liquid between two opposite, essentially planar layers, in which the two layers are arranged parallel to one another at such a distance that there is a capillary-active gap between the two layers, wherein at least one of the two layers contains at least two discrete adjacent parts and capillary-active transport of the liquid is possible beyond the common boundary of the parts that lie in one layer.

Abstract: New dye-polysaccharide and dye-cyclosaccharide conjugates and their use as a diagnostic agent especially for determining the glomerular filtration rate in humans.

Abstract: A fibrinolytically active plasminogen activator of the tissue type, wherein the growth factor (G) domain has been deleted, and wherein also the K1 domain has been deleted and additionally has been modified in one or more of the following sites or region: the sites of amino acid residues 177, 184, 277 and 448 and the F domain, the F domain modification if present being a deletion of part or all of said domain; DNA-sequence comprising a nucleotide sequence coding for said plasminogen activator; expression vector which in a transformed host cell can express said DNA-sequence; host cell transformed using such vector; pharmaceutical composition comprising the fibrinolytically active plasminogen activator; plasminogen activator for use in treating thrombotic disease; a process for the manufacture of such fibrinolytically active plasminogen activator; a process for the treatment of thrombotic disorder; and a process of localizing thrombi while using such plasminogen activator.

Abstract: The invention relates to use of ibandronic acid (1-hydroxy-3-(N-methyl-N-pentyl)aminopropyl-1,1-diphosphonic acid) or physiologically compatible salts or esters thereof for improving the osseointegration of cement-free anchored endoprostheses. Ibandronate or salts thereof is applied for a short time immediately after insertion of an endoprosthesis, with the surprising result that secondary stability of the implant is obtained in only 5 weeks or less after the operation.

Abstract: The combination of erythropoietin and calcium, with or without phosphates, is useful for treating haemochromatoses. A method for treating primary haemochromatoses in a patient involves administering to the patient a combination therapy including an erythropoietin preparation and a calcium preparation, where the erythropoietin preparation and the calcium preparation are each administered from 1 to 5 times weekly. Beneficially, this combination therapy further administers a phosphorus preparation.

Abstract: The invention concerns a process for diagnosis of an HIV infection by means of an immunoassay using the specific detection of the p24 antigen of HIV1, HIV1-Sub0 and/or the p26 antigen of HIV2, at least one antibody against the env region of HIV1, HIV1-Sub0 and/or of HIV2 and at least one antibody against the pol and/or gag region of HIV1, HIV1-Sub0 and/or HIV2, reagent kits and test strips suitable for diagnostic procedure as well as monoclonal antibodies against p24 and their use.

Abstract: The invention concerns a process for the production of a polypeptide with suitable glycosylation by culturing eukaryotic cells and isolating the polypeptide from the culture medium or/and the cells. In this process the desired glycosylated polypeptide can be produced recombinantly with the aid of endogenous gene activation or be produced naturally by the cells.

Abstract: System and process for isolating purified biological materials with a collecting unit which has collecting vessels that are accessible from above with a matrix unit in which matrix vessels are arranged in a holder as well as a closure unit which can be placed on the collecting unit to close the collecting vessel. In addition the invention also concerns a system having a collecting unit, a matrix unit, and a closure unit as well as a lysis unit and a waste unit. Moreover a new closure arrangement is disclosed which is suitable for closing vessels in which there is excess pressure.

Abstract: A bioreaction module for biochemical reactions, in particular for cell-free polypeptide biosynthesis, having a housing (1) including a system chamber (12) and a supply chamber (10), wherein the system chamber (12) contains a producing system during the biochemical reaction and the supply chamber (10) contains a supply liquid during the biochemical reaction, and the system chamber (12) and the supply chamber (10) are separated by a semi-permeable membrane (7). The housing (1) comprises a system chamber element (5) and at least one supply chamber element (3) between which the semi-permeable membrane (7) is mounted in such a manner that the system chamber (12) is defined by the system chamber element (5) and the semi-permeable membrane (7) and the supply chamber (10) is defined by the supply chamber element (3) and the semi-permeable membrane (7).

Abstract: The present invention concerns new amino alcohol derivatives, a process for their production as well as pharmaceutical preparations and reagents which contain these substances.

Abstract: Ready-to-use, aqueous injection solutions containing carvedilol (1-(9H-carbazolyl-4-yloxy)-3-[[(2-(2-methoxyphenoxy)ethyl]-amino]-2-propanol) or its pharmacologically harmless salts which are stable in storage and are well tolerated by veins are disclosed.

Abstract: A method is described for the direct, exponential amplification and sequencing (“DEXAS”) of a DNA molecule from a complex mixture of nucleic acids, wherein truncated DNA molecules as well as DNA molecules of full length are synthesized simultaneously and exponentially between two positions on the said DNA molecule, which initially contains a DNA molecule in a thermocycling reaction, a first primer, a second primer, a reaction buffer, a thermostable DNA polymerase, a thermostable pyrophosphatase (optionally), deoxynucleotides or derivatives thereof and a dideoxynucleotide or derivatives thereof. In a preferred embodiment of the method of the invention, direct sequencing of RNA can be performed using one polymerase having a Tabor-Richardson mutation, or a functional derivative thereof, and reverse transcriptase activity. In a more preferred embodiment of the method of the invention, direct sequencing of RNA can be performed in one step, in one vessel.

Abstract: A blood withdrawal system for withdrawing blood for diagnostic purposes including a lancing device having a housing with an opening and a support surface, and a lancet holder movably mounted in the opening including a lancet and a bearing member that rests on the support surface. The device further includes a trigger unit which, when moved linearly, causes a rotational movement to initiate a lancing process.

Abstract: The invention concerns a method for the determination of antigen-specific antibodies of the immunoglobulin G class in the presence of immunoglobulins of the M class in body fluids by incubation with at least two different receptors R1 and R2 and optionally additional receptors, an essential component of R2 being a binding partner in monomeric form, a reagent for determining an antigen-specific antibody of the immunoglobulin G class as well as the use of binding partners in monomeric form for the determination of an antigen-specific antibody of the immunoglobulin G class.

Abstract: Novel HCV peptide antigens are described representing partial sequences of the C-100-3 and env/core with C-regions. These peptide antigens are suitable for the determination of HCV antibodies as immunogens for the production of antibodies against HCV and as vaccines for the production of vaccines against HCV.

Abstract: The invention concerns calibrators or calibration solutions which are based on a human serum matrix and which are used in a method for detecting cytokeratin, a process for producing them, a method for stabilizing cytokeratin and an immunological method for detecting cytokeratin in a sample.

Abstract: The invention concerns a method for the purification of a target substance from a biological sample by immobilizing the target substance on a solid phase by means of a high affinity binding pair and subsequently eluting it by adding a partner of the binding pair in a free form. In addition reagent kits for carrying out the method are disclosed.

Abstract: The invention concerns monoclonal antibodies against a complex of human ACT and a serine protease, preferably against a ACT-PSA, which have essentially no cross-reactivity with free, non-complexed human ACT and with free, non-complexed PSA, as well as diagnostic test methods for detecting serine protease-ACT complexes, in particular PSA-ACT, using these monoclonal antibodies.

Abstract: Analysis device for analyzing samples, in particular of body liquids, with respect to components contained therein. It comprises a plurality of liquid handling (LH) stations. At at least a part of the LH stations there is a production of liquid waste whereby said LH-station form liquid waste sources. The liquid waste is evacuated, with at least one pump, from the liquid waste sources, with different proportions of air, via a liquid waste conducting system, into a liquid waste container. A substantial reduction of foam production is obtained by connecting at least two liquid waste sources to the liquid waste container via at least two liquid waste lines leading separately into the liquid waste container, whereas liquid waste sources with a higher average air proportion are connected to a first liquid waste line and liquid waste sources with a lower average air proportion are connected to a second liquid waste line.

Abstract: The invention concerns a method for the immunological determination of a specific antibody in a sample liquid in which the sample liquid is incubated in the presence of a solid phase with two antigens directed against the antibody to be determined of which the first antigen carries at least one marker group and the second antigen is (a) bound to the solid phase or (b) is present in a form capable of binding to the solid phase and the antibody to be determined is detected by determining the marker group in the solid phase or/and in the liquid phase characterized in that at least one of the two antigens contains several epitope regions which react with the antibody to be determined.